Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

Katharine L Lewis, FRCPath, MRCP, MBBS, Kate Manos, MBBS, John Casey, FRACP,FRCPA,MBBS, Julie Crawford, MDMBBS,FRACP, Shir-Jing Ho, FRACP,FRCPA,MBBS, Samar Issa, FRACP, Andrew Grigg, Peter Wood, Maher K. Gandhi, PhD, Eliza A Hawkes, Chan Y. Cheah

Blood (2019) 134 (Supplement_1): 1620.

https://doi.org/10.1182/blood-2019-125730

Published: 2019

Journal Articles

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Blood (2019) 134 (Supplement_1): 2879.

https://doi.org/10.1182/blood-2019-122830

Published: 2019

Journal Articles

Exploring the Safety and Efficacy of Upfront Autologous Stem Cell Transplantation with LEED Preconditioning for Primary Central Nervous System Lymphoma

Hirofumi Yokota, MD, Kotaro Miyao, MD PhD, Fumiya Ohara, MD, Kenta Motegi, MD, Hiroya Wakabayashi, MD, Yuki Takeuchi, MD, Shihomi Kuwano, MD, Hitomi Sawa, MD, Yuichiro Inagaki, MD PhD, Masashi Sawa, MD PhD

Blood (2019) 134 (Supplement_1): 1611.

https://doi.org/10.1182/blood-2019-123703

Published: 2019

Journal Articles

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Kathryn Lurain, MD MPH, Thomas S. Uldrick, MD MS, Priscila H. Goncalves, MD, Ramya Ramaswami, MBBS, MPH, Mark N. Polizzotto, Anaida Widell, Seth M. Steinberg, PhD, Elaine S. Jaffe, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Richard F. Little, MD MPH, Robert Yarchoan, MD

Blood (2018) 132 (Supplement 1): 2963.

https://doi.org/10.1182/blood-2018-99-112169

Published: 2018

Journal Articles

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Diego Villa, MD, Graham W Slack, MD PhD, Muntadhar Al-Moosawi, MD, Susana Ben-Neriah, BSc, Tamara Shenkier, MD, Joseph M. Connors, MD, Laurie H Sehn, MDMPH, Kerry J Savage, BSc, MD MSc, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD, Randy D. Gascoyne, MD, King Tan, MD

Blood (2018) 132 (Supplement 1): 348.

https://doi.org/10.1182/blood-2018-99-114218

Published: 2018

Journal Articles

Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma

Khoan Vu, MD, James Rubenstein, MD PhD, Gabriel N. Mannis, MD, Jimmy Hwang, PhD, Huimin Geng, PhD

Blood (2018) 132 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2018-99-112767

Published: 2018

Journal Articles

Outcomes Associated with Therapeutic Anticoagulation in Patients with Brain Metastasis

Shafia Rahman, MD, Fahrettin Covut, MD, Yihong Zhou, MD, Shab E Gul Rahim, MD, Sudha Amarnath, MD, Alok A. Khorana, MD

Blood (2018) 132 (Supplement 1): 1242.

https://doi.org/10.1182/blood-2018-99-119686

Published: 2018

Journal Articles

High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Jaewon Hyung, MD, Jung Yong Hong, MD, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Chan-Sik Park, Sang Wook Lee, Jin-Sook Ryu, Jooryung Huh, Cheolwon Suh

Blood (2018) 132 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2018-99-118222

Published: 2018

Journal Articles

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Blood (2018) 132 (Supplement 1): 572.

https://doi.org/10.1182/blood-2018-99-111901

Published: 2018

Journal Articles

Clinical Features and Cell of Origin Subtyping Using Gene Expression Profiling in HIV-Negative Patients with Primary Central Nervous System Lymphoma

Talal Hilal, MBB Chir, Alanna Maguire, PhD MSc, Heidi E. Kosiorek, MS, Lisa M. Rimsza, MD, Allison C. Rosenthal, DO

Blood (2018) 132 (Supplement 1): 2977.

https://doi.org/10.1182/blood-2018-99-110660

Published: 2018

Journal Articles

Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study

Jacoline Bromberg, MD, Samar Issa, FRACP, Katerina Bukanina, Monique C Minnema, Tatjana Seute, MD, Marc Durian, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Harry C. Schouten, MD, Wendy B Stevens, MD, Josée Zijlstra, MD, Johanna W. Baars, MD PhD, Marcel Nijland, MD, Kylie Mason, MBBS,PhDFRACP,FRCPA, Aart Beeker, MD, Martin van den Bent, MD, Daphne de Jong, Prof Dr, Michael Anthony Gonzales, BSc, Jeanette K. Doorduijn, MD PhD

Blood (2017) 130 (Supplement 1): 582.

https://doi.org/10.1182/blood.V130.Suppl_1.582.582

Published: 2017

Journal Articles

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Elisabeth Schorb, MD, Chris P Fox, Benjamin Kasenda, MDPhD, Teresa Calimeri, MDPhD, Kim Linton, MBChB PhD, Jeffery Smith, MBChB BMedSci MRCP FRCPath, Slavisa Ninkovic, MBBS FRACP FRCPA, Deborah Yallop, MBBS FRCP FRCPath PhD, Hans-Guido Holl, MD, Alberto Fabbri, MD, Thomas E C Cummin, MRCP MBBCh BSc, Gerald Illerhaus, MD, Kate Cwynarski, PhDMD, Andrés J M Ferreri, MD

Blood (2017) 130 (Supplement 1): 376.

https://doi.org/10.1182/blood.V130.Suppl_1.376.376

Published: 2017

Journal Articles

Efficacy and Safety of Intensive Etoposide Aracytine Consolidation Following Rituximab Methotrexate Temozolomide Induction in Newly Diagnosed Primary Central Nervous System Lymphoma

Blood (2017) 130 (Supplement 1): 1573.

https://doi.org/10.1182/blood.V130.Suppl_1.1573.1573

Published: 2017

Journal Articles

Aids Related Primary Central Nervous System Lymphoma Is Still a Challenge in the Cart Era: A Single Centre Experience

Alessandro Re, MD, Chiara Cattaneo, MD, Salvatore Casari, MD, Annalisa Peli, MD, Nicola Bianchetti, MD, Angela Passi, MD, Emanuele Focà, MD, Maria Miscio, Francesco Castelli, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 5223.

https://doi.org/10.1182/blood.V130.Suppl_1.5223.5223

Published: 2017

Journal Articles

Reduction of Immunosuppression Does Not Significantly Impact Incidence of Renal Transplant Graft Rejection Following a Diagnosis of Post-Transplant Lymphoproliferative Disorder

Emily K Fay, MD, Abdolreza Haririan, MD MPH, Arnob Banerjee, MDPhD, Seung-Tae Lee, MD PhD, Jennie Y Law, MD

Blood (2017) 130 (Supplement 1): 5216.

https://doi.org/10.1182/blood.V130.Suppl_1.5216.5216

Published: 2017

Journal Articles

Primary Dural Diffuse Large B-Cell Lymphoma Is Associated with Good Prognosis and Is Effectively Treated with CHOP-R Alone

Zachary L. Quinn, MD, Karam Zakharia, MD, Lei Yin, MS Candidate, Theresa C. Brown, PhD, John J. Schmieg, MD PhD, Hana Safah, MD, Nakhle S. Saba, MD

Blood (2017) 130 (Supplement 1): 4166.

https://doi.org/10.1182/blood.V130.Suppl_1.4166.4166

Published: 2017

Journal Articles

Methotrexate-Cytarabine-Dexamethasone Combination Chemotherapy with or without Rituximab in Patients with Primary Central Nervous System Lymphoma

Jing Liu, Xuefei Sun, Xueyan Bai, Yuedan Chen, Jun Qian, Hong Zhu, Yaming Wang, Nan Ji, Shengjun Sun, Yajie Wang, Yuanbo Liu

Blood (2016) 128 (22): 4218.

https://doi.org/10.1182/blood.V128.22.4218.4218

Published: 2016

Journal Articles

The Relapsed - Memorial Sloan - Kettering Cancer Center (R-MSKCC) Prognostic Score Is a Risk-Stratification Model for the Central Nervous System (CNS) Involvement at Relapse in Patients with Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab Era

Noriko Nishimura, MD PhD, Yasuhito Terui, MD PhD, Kengo Takeuchi, MD PhD, Naoko Tsuyama, MD, Anna Takahashi, MD, Norihito Inoue, MD, Hirofumi Yamauchi, MD, Yoshiharu Kusano, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 4221.

https://doi.org/10.1182/blood.V128.22.4221.4221

Published: 2016

Journal Articles

Primary Central Nervous System Lymphoma Treatment Outcomes-a Decade's Experience from a Single Centre in Riyadh, Saudi Arabia

Imran K Tailor, MBBS, MD FRCP, FRCPath, Taimoor Hussain, MBBS FCPS, Wafa Shakweer, Ibraheem H Motabi, MRCP MD, Ghulam Murtaza, MBBS, FCPS, Syed Ziauddin A. Zaidi, MBBS, FRCP, FRCPath, FACP, Nawal F Shehry, Mubarak S. AlGhamdi, MD, Yasser Bayoumi, MD, Samer Mudaibigh, MD SBIM, SBAH

Blood (2016) 128 (22): 5416.

https://doi.org/10.1182/blood.V128.22.5416.5416

Published: 2016

Journal Articles

Secondary Central Nervous System Involvement with Concurrent Diffuse Large B Cell Lymphoma at Initial Presentation or at Relapse Is Associated with Zero Survival- a Decade's Experience from a Single Centre in Riyadh, Saudi Arabia

Imran K Tailor, MBBS, MD FRCP, FRCPath, Taimoor Hussain, MBBS FCPS, Wafa Shakweer, Ghulam Murtaza, MBBS, FCPS, Ibraheem H Motabi, MRCP MD, Syed Ziauddin A. Zaidi, MBBS, FRCP, FCPS, FRCPath, FACP, Nawal F Shehry, Yasser Bayoumi, MD, Mubarak S. AlGhamdi, MD

Blood (2016) 128 (22): 5417.

https://doi.org/10.1182/blood.V128.22.5417.5417

Published: 2016

NARROW

Outcomes for Patients with Primary or Secondary Central System Lymphoma Treated with Ibrutinib: A Multicentre Retrospective Analysis

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Exploring the Safety and Efficacy of Upfront Autologous Stem Cell Transplantation with LEED Preconditioning for Primary Central Nervous System Lymphoma

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma

Outcomes Associated with Therapeutic Anticoagulation in Patients with Brain Metastasis

High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Clinical Features and Cell of Origin Subtyping Using Gene Expression Profiling in HIV-Negative Patients with Primary Central Nervous System Lymphoma

Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Efficacy and Safety of Intensive Etoposide Aracytine Consolidation Following Rituximab Methotrexate Temozolomide Induction in Newly Diagnosed Primary Central Nervous System Lymphoma

Aids Related Primary Central Nervous System Lymphoma Is Still a Challenge in the Cart Era: A Single Centre Experience

Reduction of Immunosuppression Does Not Significantly Impact Incidence of Renal Transplant Graft Rejection Following a Diagnosis of Post-Transplant Lymphoproliferative Disorder

Primary Dural Diffuse Large B-Cell Lymphoma Is Associated with Good Prognosis and Is Effectively Treated with CHOP-R Alone

Methotrexate-Cytarabine-Dexamethasone Combination Chemotherapy with or without Rituximab in Patients with Primary Central Nervous System Lymphoma

The Relapsed - Memorial Sloan - Kettering Cancer Center (R-MSKCC) Prognostic Score Is a Risk-Stratification Model for the Central Nervous System (CNS) Involvement at Relapse in Patients with Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab Era

Primary Central Nervous System Lymphoma Treatment Outcomes-a Decade's Experience from a Single Centre in Riyadh, Saudi Arabia

Secondary Central Nervous System Involvement with Concurrent Diffuse Large B Cell Lymphoma at Initial Presentation or at Relapse Is Associated with Zero Survival- a Decade's Experience from a Single Centre in Riyadh, Saudi Arabia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only